James Paparello
Overview
Explore the profile of James Paparello including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
44
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Naidech A, Wang H, Hutch M, Murphy J, Paparello J, Bath P, et al.
BMJ Neurol Open
. 2023 Aug;
5(2):e000458.
PMID: 37529670
Background: Acute blood pressure (BP) reduction is standard of care after acute intracerebral haemorrhage (ICH). More acute BP reduction is associated with acute kidney injury (AKI). It is not known...
2.
Riaz A, Portocarrero J, Hoel A, Yeldandi A, Dellefave-Castillo L, Paparello J, et al.
Circ Genom Precis Med
. 2021 Sep;
14(5):e003386.
PMID: 34587764
No abstract available.
3.
Barsuk J, Paparello J, Cotts W
J Hosp Med
. 2011 Dec;
7(3):167-9.
PMID: 22162499
No abstract available.
4.
Posadas M, Hahn D, Schleuter W, Paparello J
Hemodial Int
. 2011 Jun;
15(3):416-23.
PMID: 21711442
We present a case of a 51-year-old woman who developed thrombocytopenia associated with dialysis treatments. Laboratory values revealed a platelet count of 50,000 or less postdialysis, with recovery of platelet...
5.
Naidech A, Paparello J, Liebling S, Leibling S, Bassin S, Levasseur K, et al.
Neurocrit Care
. 2010 Jun;
13(1):57-61.
PMID: 20568023
Background: Hyponatremia is common in neurocritical care and is associated with poor outcome, but the optimal treatment is not known. We wished to test the hypothesis that for neurocritical care...
6.
Lam A, Shah S, Paparello J
Dis Mon
. 2010 Mar;
56(4):215-32.
PMID: 20350654
There is increasing emphasis on chronic kidney disease (CKD), owing to its prevalence and its association with cardiovascular risk. Important issues concerning treatment of CKD are delaying its progression, improving...
7.
Kurkjian C, Kummar S, Stewart D, Waxman K, Lam A, Shah S, et al.
Dis Mon
. 2010 Mar;
56(4):187-250.
PMID: 20350652
No abstract available.
8.
Lam A, Shah S, Paparello J
Am J Ther
. 2008 May;
15(3):278-86.
PMID: 18496265
There is increasing emphasis on chronic kidney disease (CKD), owing to its prevalence and its association with cardiovascular risk. Important issues concerning treatment of CKD are delaying its progression, improving...
9.
Serrano A, Huang J, Ghossein C, Nishi L, Gangavathi A, Madhan V, et al.
Adv Chronic Kidney Dis
. 2007 Jan;
14(1):105-12.
PMID: 17200050
This study examines whether stabilization of the glomerular filtration rate (GFR) is possible in patients with advanced chronic kidney disease (CKD), managed in a CKD clinic. A cohort of 82...
10.
Shah S, Paparello J, Danesh F
Adv Chronic Kidney Dis
. 2005 Apr;
12(2):187-95.
PMID: 15822054
Statins are lipid-lowering agents that specifically, competitively, and reversibly inhibit 3-hydroxy-3-methylglutaryl coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in...